INCB000928
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for INCB000928, covering 2025-10-22 to 2025-12-23. Get the full timeline:
Most recent: Clinical Trial Update: INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders [Phase 1, Phase 2]